目的：研究分析沙格列汀联合二甲双胍治疗2型糖尿病患者临床疗效。方法：选取收治的2型糖尿病患者200例，分为对照组与研究组，其中对照组给予二甲双胍进行治疗，研究组在对照组基础上给予沙格列汀进行治疗，比较两组患者治疗前后空腹血糖、餐后2h 血糖、C 肽变化情况。结果：两组患者 FPG、1hFPG、2hFPG、HbA1cFCP、CP1h、CP2h、HOMA －IR 及 HOMA －β的值治疗前后均有明显改善，差异有统计学意义（P ＜0.05），且观察组的改善程度明显高于对照组，差异有统计学意义（P ＜0.05）。对照组不良反应发生率为11％，研究组为14％，两组之间比较，差异无统计学意义（P ＞0.05）。结论：沙格列汀联合二甲双胍治疗2型糖尿病临床疗效优异，可有效控制患者血糖，改善胰岛功能，不良反应少，安全性高，值得临床广泛推广应用。%Objective To study the clinical efficacy of Shah Glenn Dean combined with metformin in the treatment of type 2 diabetes mellitus.Method 200 patients with type 2 diabetes were divided into control group and study group,the control group was given metformin treatment,research group in the control group were given the Shah Glenn Dean treatment,two groups were compared before and after treatment of fasting blood glucose,postprandial 2H blood glucose,C peptide changes.Results Two groups of patients with FPG,1hFPG,2hFPG,HbA1cFCP,CP1h,CP2h,HOMA -IR and HOMA - beta value before and after treatment were significantly improved (P <0.05),and the improvement of the observation group was significantly higher than the control group (P <0.05).The incidence of adverse reactions in the control group was 11%,the study group was 14%,there was no significant difference between the two groups,no statistical significance (P >0.05).Conclusion Pioglitazone combined with metformin in the treatment of type 2 diabetes with excellent clinical efficacy,can effectively control blood glucose,improve islet function,less adverse reactions,high safety,worthy of clinical application.
展开▼
